From Name:
From Email:
To Name:
To Email:

Optional Message:

Orphaned UA Drug Licensed to Company to Treat Canine Cancer

from University of Arizona

Garth Powis, Ph.D., formerly of the University of Arizona, College of Medicine in collaboration with colleagues at the University of Pittsburgh, Sanford Burnham Prebys Medical Discovery Institute, and Cascadian Pharmaceuticals, has developed a novel kinase inhibitor, PX-886, which is efficacious for the treatment of a variety of solid tumors in canines. The University of Arizona has exclusively licensed the rights to PX-886 to Anivive Lifesciences, who is developing PX-866 as a best in class treatment for solid tumors in canines. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063